The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index; 8 of the 54 sources its claims cite were checked for support.
Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature
Open accessAbstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a distinct form of interstitial pneumonia with unknown origin and poor prognosis. Current pharmacologic treatments are limited and lung transplantation is a viable option for appropriate patients. The aim of this review was to summarize lung transplantation survival in IPF patients overall, between single (SLT) vs. bilateral lung transplantation (BLT), pre- and post Lung Allocation Score (LAS), and summarize wait-list survival. METHODS: A systematic review of English-language studies published in Medline or Embase between 1990 and 2013 was performed. Eligible studies were those of observational design reporting survival post-lung transplantation or while on the wait list among IPF patients. RESULTS: Median survival post-transplantation among IPF patients is estimated at 4.5 years. From ISHLT and OPTN data, one year survival ranged from 75% - 81%; 3-year: 59% - 64%; and 5-year: 47% - 53%. Post-transplant survival is lower for IPF vs. other underlying pre-transplant diagnoses. The proportion of IPF patients receiving BLT has steadily increased over the last decade and a half. Unadjusted analyses suggest improved long-term survival for BLT vs. SLT; after adjustment for patient characteristics, the differences tend to disappear. IPF patients account for the largest proportion of patients on the wait list and while wait list time has decreased, the number of transplants for IPF patients has increased over time. OPTN data show that wait list mortality is higher for IPF patients vs. other diagnoses. The proportion of IPF patients who died while awaiting transplantation ranged from 14% to 67%. While later transplant year was associated with increased survival, no significant differences were noted pre vs. post LAS implementation; however a high LAS vs low LAS was associated with decreased one-year survival. CONCLUSIONS: IPF accounts for the largest proportion of patients awaiting lung transplants, and IPF is associated with higher wait-list and post-transplant mortality vs. other diagnoses. Improved BLT vs. SLT survival may be the result of selection bias. Survival pre- vs. post LAS appears to be similar except for IPF patients with high LAS, who have lower survival compared to pre-LAS. Data on post-transplant morbidity outcomes are sparse.
Overview
CoChat Summary
TL;DR
This systematic review found that lung transplantation offers a survival benefit for IPF patients, but their post-transplant and wait-list mortality remain worse than for other diagnoses. Evidence suggested better unadjusted outcomes for bilateral over single lung transplantation, but those differences often disappeared after adjustment, pointing to likely selection bias.
Key findings
- The review included 54 publications; the literature search identified 1,375 citations, screened 385 full-text articles, and excluded 331 at full-text review.
- Among 8,528 IPF patients transplanted from 1990 to 2011 in ISHLT data, median survival was 4.5 years; survival was 75% at 1 year, 59% at 3 years, 47% at 5 years, and 24% at 10 years.
- In OPTN data, IPF patients’ 1-, 3-, and 5-year post-transplant survival ranged from 75%–81%, 59%–64%, and 47%–53%, respectively; post-transplant survival was lower for IPF than for CF, COPD, or alpha-1 antitrypsin deficiency.
- Wait-list burden was high: in 2011, IPF accounted for 46.1% of lung transplant wait-list patients in the US, and the proportion who died while waiting ranged from 14% to 67% across studies; OPTN wait-list mortality was higher for IPF than for other diagnoses.
- For BLT vs. SLT, unadjusted analyses often favored BLT: in one OPTN analysis of 3,830 IPF patients, mean survival was 8.34 years for BLT vs. 7.37 years for SLT, but after adjustment the difference was no longer statistically significant (HR 0.92, 95% CI 0.81–1.06).
Methods
- Systematic review of English-language observational studies in MEDLINE/EMBASE from 1990 to March 2013, supplemented by manual reference checking and data from ISHLT and OPTN websites.
- Included studies had to report on at least 10 IPF patients who underwent lung transplantation and report survival post-transplant or while waiting.
- The review extracted study-, patient-, and outcome-level data; one investigator extracted data and a second independently checked it for completeness and accuracy.
Limitations
- The paper states that data on post-transplant morbidity and resource use are sparse.
- The paper also states that a limitation is the lack of actual confirmation of IPF in most of the studies.
- Evident from the text: much of the evidence comes from observational studies, so comparisons such as BLT vs. SLT and pre- vs. post-LAS are vulnerable to selection bias and confounding, which the authors explicitly discuss.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
6 Valid · 0 Not valid · 34 Not checked · 18 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Long-term survival, conditional to surviving one-year, was also significantly (P < 0.0006) better for patients who received a BLT vs. SLT (12.08 years versus 6.8 years) [51].”
§ Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature > Results > Single vs. bilateral lung transplantation
What the sources say
- Supportedcites [51] Force SD, Kilgo P, Neujahr DC, Pelaez A, Pickens A, Fernandez FG, Miller DL, Lawrence C: Bilateral lung transplantation offers better long-term survival, compared with single-lung transplantation, for younger patients with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2011, 91 (1): 244-249. 10.1016/j.athoracsur.2010.08.055. source
The Results section (page not provided) reports significantly better long-term survival for BLT than SLT among patients alive at one year: 12.08 versus 6.8 years (p = 0.0006). (LLM, conf=0.95)
plainstates an associationn = 3,830 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
In the paper
“Data available via the OPTN web site demonstrated that long-term post-transplant survival among US IPF lung transplant recipients transplanted between 1997 – 2004 was lower (3-year: 57%; 5-year: 41%) [19].”
§ Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature > Results > Post-transplant survival
What the sources say
- Not matchedcites [19] OPTN data. [ http://optn.transplant.hrsa.gov/latestData/rptData.asp ]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“However, the difference was not evident in an analysis restricted to 1,218 patients who had lung transplantation from 2002 onward (BLT: 5.0 years vs SLT: 4.6 years, P = 0.29).”
§ Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature > Results > Single vs. bilateral lung transplantation
What the sources say
- Not checked — no full text of the sourcecites [21] Thabut G, Christie JD, Ravaud P, Castier Y, Dauriat G, Jebrak G, Fournier M, Leseche G, Porcher R, Mal H: Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. Ann Intern Med. 2009, 151 (11): 767-774. 10.7326/0003-4819-151-11-200912010-00004. source
plainn = 1,218- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“From the 8,528 IPF patients transplanted from 1990 to 2011 and reported to the ISHLT, the median survival was 4.5 years [12].”
§ Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature > Results > Post-transplant survival
What the sources say
- Not matchedcites [12] Adult Lung Transplantation Statistics. [ https://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry ]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainn = 8,528- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“Another analysis of the OPTN data that included 3,327 IPF patients transplanted between 1997 and 2009 also found significantly (P < 0.001) longer median survival after BLT (5.2 years [95% CI, 4.3 to 6.7 years]) vs. SLT (3.8 years [95% CI, 3.6 to 4.1 years]) [21].”
§ Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature > Results > Single vs. bilateral lung transplantation
What the sources say
- Not checked — no full text of the sourcecites [21] Thabut G, Christie JD, Ravaud P, Castier Y, Dauriat G, Jebrak G, Fournier M, Leseche G, Porcher R, Mal H: Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. Ann Intern Med. 2009, 151 (11): 767-774. 10.7326/0003-4819-151-11-200912010-00004. source
plainstates an associationn = 3,327 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
25 more claims
Create a free account to see all 58 claims and to verify the 6 references still open.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 20
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature > Results > Post-transplant survival vs. wait list survival
“In 2011, patients with IPF accounted for the largest proportion (46.1%) of patients on the lung transplant wait-list in the US [19].”
§ Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature > Background
“Since the implementation of the LAS system in the US, the percentage of patients on the wait list with restrictive lung disease (i.e., IPF or re-transplants) has increased from 33.8% to 46.1% [11].”
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,175
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,665
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Systematic Reviews: Synthesis of Best Evidence for Clinical Decisions
Cook, D. J., Mulrow, C. D., & Haynes, R. B. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-5-199703010-00006 · Cited by 2,184 · cited 1×
“The methods used to perform this review involved both electronic and manual components, and followed established best methods used in the science of systematic review research [15-17].”
MethodIncidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · cited 1×
“Using a prevalence of 14–43 per 100,000 [73] and a US adult population of approximately 311 million in 2011 [74], less than 1% of the estimated 42,000–130,000 US IPF patients had received a lung transplant during 2011.”
BackgroundAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Orens, J. B., Estenne, M., Arcasoy, S., Conte, J. V., Corris, P., Egan, J. J., Egan, T., Keshavjee, S., Knoop, C., Kotloff, R., et al. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2006.03.011 · Cited by 1,073
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 1×
“The median survival time for patients with IPF is 2 to 3 years from diagnosis and the 5-year survival rate ranges between 30% and 50% [1,5-7].”
Background
Research works printed but not linked: 1
- Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR): OPTN/SRTR 2011 Annual Data Report. 2012, Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation
Cited by
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Martinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.74 · Cited by 1,388
European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers
Bonella, F., Wijsenbeek, M. S., Molina‐Molina, M., Duck, A., Mele, R., Geissler, K. H., & Wuyts, W. A. (2015) · European Respiratory Journal · doi:10.1183/13993003.01204-2015 · Cited by 144
Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes
Sauleda, J., Núñez, B., Sala, E., & Soriano, J. B. (2018) · Medical Sciences · doi:10.3390/medsci6040110 · Cited by 155
“Whether bilateral is superior to single-lung transplantation in patients with IPF is still unclear, although observational studies and available databases suggest improved outcomes with bilateral transplantation [60].”
Metadata
- Authors
- Kistler, K. D., Nalysnyk, L., Rotella, P., & Esser, D.
- Affiliations
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Kistler, Kristin D
- ORCID
- Kistler, Kristin D
- Venue
- BMC Pulmonary Medicine
- Published
- 2014-08-16
- Volume
- 14
- Issue
- 1
- Pages
- 139-139
- ISSN
- 1471-2466 (ISSN-L)
- PMC
- PMC4151866
- OpenAlex
- W2039943389
- Cited by
- 151
- References
- 77
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 16 · 2023: 8 · 2022: 13 · 2021: 15 · 2020: 13 · 2019: 13 · 2018: 25 · 2017: 18 · 2016: 11 · 2015: 7 · 2014: 1
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Pulmonary Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, lung transplantation, bilateral lung transplantation, single lung transplantation, lung allocation score, waitlist mortality, post-transplant survival, interstitial lung disease, OPTN registry, ISHLT registry
- MeSH terms
- Graft Survival, Humans, Waiting Lists, Survival Rate, Lung Transplantation, Idiopathic Pulmonary Fibrosis, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. https://app.cochat.ai/papers/10.1186/1471-2466-14-139
- The paper
- Kistler, K. D., Nalysnyk, L., Rotella, P., & Esser, D. (2014). Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulmonary Medicine. https://doi.org/10.1186/1471-2466-14-139
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

